• Windtree Therapeutics agreed to sell Seismic Pharmaceuticals’ cardiovascular program assets to Seismic Pharmaceuticals Operations in an asset purchase agreement dated Dec. 16, 2025.
• Upfront consideration totals USD 150,000 cash at closing.
• Windtree can receive USD 700,000 if the buyer completes a post-closing financing of at least USD 10 million.
• Windtree is also entitled to 20% of certain license-out economics tied to the transferred intellectual property, with a USD 1.2 million buyout option following a qualifying financing.
• The deal includes a planned transfer of control of a Taiwanese subsidiary effective no earlier than Jan. 1, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Windtree Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-26-024009), on July 22, 2026, and is solely responsible for the information contained therein.